Connecticut Life Sciences: Biotech News, Research & Innovations
Welcome to the AdvanceCT LinkedIn newsletter. Stay up to date with the latest news from our team and all things Connecticut by subscribing.
Our team is exhibiting at the BIO International Convention this week. Make sure to stop by, booth #2425, to learn more about the thriving bioscience ecosystem in Connecticut.
Expansions and Collaborations
XSeed Labs, a collaboration between BioMed X Institute and 勃林格殷格翰 , has launched its first research team at Boehringer Ingelheim’s U.S. headquarters in Ridgefield, Connecticut. Led by Dr. Lorenzo Tala, the team’s primary objective is to develop complex, physiologically relevant disease models to better understand dysfunctional wound healing and fibrosis. Heidelberg, Germany-based BioMed X established its first U.S. institute in New Haven in 2023 with support from AdvanceCT .?
The University of Connecticut ’s (UConn) College of Engineering has established the Collaboratory for Biomedical Engineering Innovation, a hub for interdisciplinary research aimed at investing and developing new bio-based technologies. Led by Leslie Shor and Guoan Zheng, the Collaboratory fosters collaboration between biomedical and bioengineering researchers from UConn and UConn Health , promoting the adaptation of existing biotechnologies to address emerging challenges in the biological sciences.
By facilitating new interdisciplinary collaborations and promoting bio-based technologies, the Collaboratory aims to drive scientific discovery, economic growth, and workforce development in Connecticut.
Rallybio has partnered with Johnson & Johnson to develop complimentary therapeutic approaches aimed at reducing the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT). Rallybio, which received a $6.6M equity investment from 强生公司 Innovation, is advancing RLYB212, a novel monoclonal antibody designed to prevent alloimmunization in pregnant individuals, thus eliminating the risk of FNAIT.
Biohaven has acquired another property in downtown New Haven, purchasing the former bank building at 209 Church Street. This 8,900 square-foot building, constructed in 1929, is adjacent to their main headquarters at 215 Church St. The company is expanding its presence in New Haven with plans to establish a campus-type environment. Biohaven is known for developing major market drugs such as the migraine treatment Nurtec ODT and is working on therapies for neurological and psychiatric conditions, including Alzheimer’s, OCD, and ALS.
领英推荐
New Leadership
Arvinas , a clinical-stage company specializing in targeted protein degradation, has appointed Randy Teel, Ph.D., as Chief Business Officer. Dr. Teel, who is also serving as interim Chief Financial Officer and Treasurer, will remain on the Executive Committee, reporting to Chairperson, President and CEO John Houston, Ph.D.
Funding
U.S. Senators Chris Murphy and Richard Blumenthal proudly announced the inclusion of over $35.68M in the final fiscal year 2024 appropriations package, aimed at funding 38 congressionally directed spending projects across Connecticut.
These funds will support a wide range of initiatives benefiting local communities, including workforce development, health, education, and small businesses. Projects include support for workforce training programs, mental health services, infrastructure improvements, and small business development efforts.
Connecticut Innovations (C.I.), Connecticut’s venture capital arm, announced in late April that it had invested $12.6M in 24 companies and venture funds during the third quarter of its fiscal year ending March 31, 2024. The investments were distributed across the consumer ($5.5M), technology ($2.5M), and healthcare sectors ($4.6M), leveraging $148M in outside capital.
CYduct Diagnostics , a women’s health company specializing in precision medicine-based breast cancer risk assessment and diagnostic tools, has reported encouraging findings from its recent research on breast cancer biomarkers. The pilot study, utilizing liquid biopsy samples, successfully met its primary endpoint by measuring specific biomarker concentrations correlated to breast health, showing significant improvement over single biomarker assessments. While overall data results are preliminary, a promising positive trend has been observed.
Visit our website: https://www.advancect.org/
Follow us on socials: